Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Scientist's Perspective

Research output: Contribution to journal › Review › Research › peer-review

Standard

Bringing Advanced Therapies for Parkinson's Disease to the Clinic : The Scientist's Perspective. / Tomishima, Mark; Kirkeby, Agnete.

In: Journal of Parkinson's Disease, Vol. 11, 2021, p. S135-S140.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Tomishima, M & Kirkeby, A 2021, 'Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Scientist's Perspective', Journal of Parkinson's Disease, vol. 11, pp. S135-S140. https://doi.org/10.3233/JPD-212685

APA

Tomishima, M., & Kirkeby, A. (2021). Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Scientist's Perspective. Journal of Parkinson's Disease, 11, S135-S140. https://doi.org/10.3233/JPD-212685

Vancouver

Tomishima M, Kirkeby A. Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Scientist's Perspective. Journal of Parkinson's Disease. 2021;11:S135-S140. https://doi.org/10.3233/JPD-212685

Author

Tomishima, Mark ; Kirkeby, Agnete. / Bringing Advanced Therapies for Parkinson's Disease to the Clinic : The Scientist's Perspective. In: Journal of Parkinson's Disease. 2021 ; Vol. 11. pp. S135-S140.

Bibtex

@article{2d4c867950954d7d8945122f34410f4c,
title = "Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Scientist's Perspective",
abstract = "After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson's disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.",
keywords = "ATMP, clinical trial, dopaminergic neurons, regenerative therapy, stem cells, transplantation, DOPAMINE NEURONS, PRECLINICAL EFFICACY, CELL TRANSPLANTATION, STEM-CELLS, MODEL, SAFETY, PATHOLOGY, REVEALS, TRIAL",
author = "Mark Tomishima and Agnete Kirkeby",
year = "2021",
doi = "10.3233/JPD-212685",
language = "English",
volume = "11",
pages = "S135--S140",
journal = "Journal of Parkinson's Disease",
issn = "1877-7171",
publisher = "I O S Press",

}

RIS

TY - JOUR

T1 - Bringing Advanced Therapies for Parkinson's Disease to the Clinic

T2 - The Scientist's Perspective

AU - Tomishima, Mark

AU - Kirkeby, Agnete

PY - 2021

Y1 - 2021

N2 - After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson's disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.

AB - After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson's disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.

KW - ATMP

KW - clinical trial

KW - dopaminergic neurons

KW - regenerative therapy

KW - stem cells

KW - transplantation

KW - DOPAMINE NEURONS

KW - PRECLINICAL EFFICACY

KW - CELL TRANSPLANTATION

KW - STEM-CELLS

KW - MODEL

KW - SAFETY

KW - PATHOLOGY

KW - REVEALS

KW - TRIAL

U2 - 10.3233/JPD-212685

DO - 10.3233/JPD-212685

M3 - Review

C2 - 34250954

VL - 11

SP - S135-S140

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

SN - 1877-7171

ER -

ID: 281275936